ENDRA Life Sciences

ENDRA Life Sciences is on a mission to revolutionize point-of-care diagnostics by enhancing the capabilities of conventional ultrasound. Its core achievement is the development of the TAEUS® platform, which is CE-marked for liver fat quantification in Europe, targeting the vast, underserved market for early detection of fatty liver disease. The company's strategy leverages a capital-efficient, accessory-based business model to integrate with existing ultrasound systems, aiming to establish TAEUS® as a new standard of care in hepatology and expand into other tissue characterization applications.

TAEUS® (Thermo-Acoustic Enhanced UltraSound) enhances conventional ultrasound by using radio frequency energy to stimulate tissue, generating acoustic waves that allow for quantitative tissue characterization, such as liver fat measurement.

ENDRA competes with high-cost, high-accuracy MRI, point-of-care but less quantitative devices like FibroScan's CAP, and emerging software-based ultrasound algorithms. Its key differentiator is aiming to provide MRI-like quantification at an ultra-low cost and as an accessory to existing ultrasound hardware.